A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Summary

This is a Phase 2a, Open-label, one arm study in which the eligible patients will be treated with IV Nerofe, three times a week in 28 days cycles (up to 12 cycles). Evaluation will include safety procedures, blood level of study drug in certain time points, immune system response and tests checking the mechanism of the drug action.

Timeline

Start

2018-10-25

Primary completion

2020-07-26

Completion

2020-07-26

Outcome

Outcome not reported

Stopped (Enrollment): “No recruitment since initiation”

Drugs

Indications